Viking Therapeutics (LTS:0VQA) Days Payable: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0VQA Viking Therapeutics Inc LTS:0VQA
26 GF Score
Price $36.22
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Days Payable?

Viking Therapeutics LTS:0VQA -4.43% 26 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 701 Biotechnology companies, Viking Therapeutics ranks worse than 142653.21% on this metric.

Viking Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $60.22 Mil. Viking Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Viking Therapeutics's Days Payable or its related term are showing as below:

LTS:0VQA's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84
* Ranked among companies with meaningful Days Payable only.

Viking Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Viking Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Days Payable Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0VQA vs EWTX, ACAD, DNLI: Days Payable Comparison

For the Biotechnology subindustry, Viking Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Days Payable falls into.


LTS:0VQA
26GF Score
Viking Therapeutics Inc LTS:0VQA
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Viking Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (9.813 + 53.251) / 2 ) / 0*365
=31.532 / 0*365
=N/A

Viking Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (53.251 + 67.183) / 2 ) / 0*365 / 4
=60.217 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Viking Therapeutics (LTS:0VQA) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #999999 out of 701 companies in the Biotechnology industry.
Is Viking Therapeutics' Days Payable too high?
Viking Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Viking Therapeutics ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viking Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Days Payable compare to EWTX and ACAD?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #999999 out of 701 companies for Days Payable. This places Viking Therapeutics in the lower half of its industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Viking Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viking Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current Days Payable of 0.00. The current Days Payable is 0.00. Viking Therapeutics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
26GF Score

Get the complete analysis for LTS:0VQA

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.22
Price